Vascular Trial Associated Registry Pilot
ConditionPeripheral Arterial Disease
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age45+
SponsorCorewell Health West
About this trial
The purpose of this investigator-initiated, multicenter, open label, randomized trial is to evaluate 1 month vs. 6 months of dual antiplatelet therapy (DAPT) in patients undergoing lower extremity endovascular revascularization. We hypothesize that extending dual antiplatelet therapy (DAPT) to six months, compared to one month, will improve patency rates of target vessels following peripheral vascular intervention (PVI) without significantly increasing complications, particularly bleeding events.
Eligibility criteria
Qualifiers
Age greater than or equal to 45 at time of enrollment
Patient is scheduled for a PVI or has recently had a PVI in the last 30 days
Patient data is being submitted to Fivos, who is acting as the data collection subcontractor for the VQI-PVI registry.
Atherosclerotic vascular disease
Disqualifiers
Patients who cannot consent for themselves
Allergy to Clopidogrel
Patients unable to stop clopidogrel for other medical reasons
Patients on dual pathway inhibition (DPI) with low dose rivaroxaban (2.5mg twice a day) that are unable to stop these medications
Trial design
Treatments tested in this trial
- Clopidogrel (Plavix) Pharmacogenetic Test Reagents
Treatment groups
350 Participants
are divided into 2 treatment groupsSponsors and collaborators
Corewell Health West
Lead sponsor
Henry Ford Hospital
Collaborator
Source ClinicalTrials.gov